Background
SmithKline Beecham (now GlaxoSmithKline) marketed Paxil, one of the world’s best-selling antidepressants. The active ingredient is paroxetine hydrochloride hemihydrate — a crystalline form of the paroxetine salt. SmithKline owned U.S. Patent No. 4,721,723 covering paroxetine hydrochloride, and also U.S. Patent No. 6,113,944 directed to pharmaceutical tablets made by a specific process — a “product-by-process” patent that claimed tablets containing paroxetine hydrochloride hemihydrate made by a process that produced a product having distinctive characteristics such as specific tablet color, spherical granule structure, and content uniformity. SmithKline listed both patents in the FDA Orange Book.
When Apotex and TorPharm filed ANDAs to market generic paroxetine, SmithKline sued for infringement. The district court found the ‘723 patent anticipated and the ‘944 product-by-process patent also anticipated, because the prior art ‘723 patent itself disclosed paroxetine hydrochloride hemihydrate — the same product that the ‘944 patent’s product-by-process claims encompassed. SmithKline appealed.
The Court’s Holding
The Federal Circuit affirmed. Writing for the court, Judge Gajarsa applied the settled principle governing product-by-process claims: a product-by-process claim is anticipated whenever the prior art discloses the same product — regardless of whether the prior art made the product by the same process. The novelty of a product-by-process claim lies in the product, not in the process used to make it. Because the ‘723 patent had already disclosed paroxetine hydrochloride hemihydrate, the ‘944 patent’s claims to that same compound (however made) were anticipated.
SmithKline argued that the product made by the ‘944 process was a different product — that the specific manufacturing process produced tablets with distinctively different physical characteristics (pink hue, spherical granule morphology, content uniformity) that made the product patentably novel. The Federal Circuit rejected this argument because the physical characteristics cited were characteristics of the tablet formulation, not novel chemical entities — they were presentation characteristics, not inherently distinguishing molecular or crystalline features of the active pharmaceutical ingredient itself. The product was still the same paroxetine hydrochloride hemihydrate previously disclosed.
Judge Newman dissented vigorously, arguing that the majority had misapplied the product-by-process doctrine and that genuine differences in the product produced by the specific manufacturing process could support patentability.
Key Takeaways
- Product-by-process patent claims are anticipated whenever prior art discloses the same product — the novelty of the process by which the product is made is irrelevant to whether the product itself is new.
- A later product-by-process patent cannot avoid anticipation by a prior product disclosure by pointing to process-derived manufacturing characteristics (like tablet morphology) when the active ingredient and its chemical form are the same.
- Pharmaceutical manufacturers who seek secondary patents on manufacturing processes must ensure either that the process produces a genuinely different product at the molecular/crystalline level, or that they claim the process itself rather than the product-by-process.
- This decision limits the ability of brand pharmaceutical companies to extend market exclusivity through product-by-process patents on manufacturing methods for previously-disclosed drugs.
- Judge Newman’s dissent signals an ongoing debate about the scope and proper application of the product-by-process anticipation doctrine that has continued to evolve in subsequent Federal Circuit decisions.
Why It Matters
SmithKline v. Apotex is an important Hatch-Waxman and pharmaceutical patent decision addressing the limits of product-by-process claiming strategies. Brand drug companies sometimes try to extend market exclusivity for successful drugs by filing additional patents on manufacturing processes — patents that claim the product made by the improved process. This strategy can work if the manufacturing process produces a genuinely new and different product. But if the process merely produces the same product more efficiently or with different cosmetic characteristics, a product-by-process claim will fail for anticipation.
For the pharmaceutical industry, this case reinforced that effective secondary patenting strategies must target genuinely new compounds, new crystalline forms with different pharmacological properties, new dosage forms, or clearly better therapeutic outcomes — not just cosmetic differences in how a known drug is formulated or tableted. Generic companies successfully used this decision to help clear the way for generic Paxil entry, illustrating how the product-by-process anticipation doctrine can work as a tool for patent challenge in Hatch-Waxman litigation.